Stopping GLP-1s Linked to Double Heart Event Risk in T2D, Study Finds

Patients with type 2 diabetes and no prior cardiovascular disease who stopped taking GLP-1 receptor agonists faced roughly double the combined rate of heart attack, stroke or death from any cause compared with those who stayed on the drugs, according to an observational study of more than 80,000 people treated at 301 diabetes clinics across Italy between 2004 and 2024.

The research, published Nov. 9 in The Lancet Regional Health – Europe, found 3.94 events per 100 person‑years among patients who discontinued treatment versus 1.96 per 100 person‑years among persistent users — an incidence rate ratio of 2.01 (95% CI 1.77–2.28) and a hazard ratio of 2.03 (95% CI 1.92–2.14). All‑cause mortality showed an even wider gap: 2.23 deaths per 100 person‑years after discontinuation versus 0.48 among those who continued (IRR 4.67; HR 4.81).

New study shows the risk to heart health when users stop taking GLP-1 medications — CTV News

The association was stronger in patients with obesity. Those with a body‑mass index of 30 or higher had a hazard ratio of 2.27 (95% CI 2.12–2.43) for the primary composite endpoint, compared with 1.61 (95% CI 1.47–1.78) in those below that threshold, the study reported.

“[The] results of our study show that people with T2D without CVD [cardiovascular disease] who started and then interrupted a therapy with a GLP-1RA have a higher risk of a composite endpoint of myocardial infarction, stroke, or death from any cause than those persisting on the same medication at a 4-year follow-up.”

the authors, led by Antonio Ceriello of IRCCS MultiMedica in Milan, wrote in the paper.

Quitting GLP-1 drugs doubles major cardiac event risk: study — CTV News

The study used electronic medical records from over 80,000 participants in the Italian Association of Clinical Diabetologists database. Most received earlier‑generation GLP‑1 drugs; semaglutide accounted for only a small fraction of prescriptions, and tirzepatide was not included because it entered the Italian market after the study period. Persistent users took a GLP‑1 for nearly three years on average, while those who stopped did so after just over one year.

After discontinuation, weight, blood sugar and blood pressure changed only slightly, and there were no significant differences in those factors between patients who later suffered a cardiovascular event or death and those who did not, suggesting these measures may not fully explain the higher risk, the authors noted.

Antonio Ceriello, who heads the Diabetes Department at IRCCS MultiMedica in Milan, chaired the International Diabetes Federation committee that produced the 2008 guideline on postmeal glucose management and its 2011 update. He has served as Editor in Chief of Diabetes Research and Clinical Practice, the IDF’s official journal, since July 2016, and currently leads the European Association for the Study of Diabetes Study Group on Diabetes and Cardiovascular Diseases.

Stopping GLP-1 Medicines Linked to Doubled Risk of Major Cardiovascular Events or Death: Study — Medical Dialogues

Because the study was observational, unmeasured confounding and reverse causation cannot be ruled out, the researchers cautioned. The analysis lacked data on why patients stopped treatment, on socioeconomic factors, and on cause of death, and heart‑failure hospitalizations were inconsistently captured. Results may not apply to patients using GLP‑1 drugs for obesity without diabetes or to tirzepatide, which was not evaluated.